1. Home
  2. SHLS vs DBVT Comparison

SHLS vs DBVT Comparison

Compare SHLS & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shoals Technologies Group Inc.

SHLS

Shoals Technologies Group Inc.

HOLD

Current Price

$9.89

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$18.19

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHLS
DBVT
Founded
1996
2002
Country
United States
France
Employees
N/A
90
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
SHLS
DBVT
Price
$9.89
$18.19
Analyst Decision
Buy
Buy
Analyst Count
14
7
Target Price
$9.07
$32.04
AVG Volume (30 Days)
5.3M
146.9K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
42.86
10.26
EPS
N/A
N/A
Revenue
$475,331,000.00
$5,636,000.00
Revenue This Year
$26.24
$35.04
Revenue Next Year
$11.52
$2,360.78
P/E Ratio
$41.63
N/A
Revenue Growth
19.07
35.77
52 Week Low
$3.99
$7.53
52 Week High
$11.36
$26.19

Technical Indicators

Market Signals
Indicator
SHLS
DBVT
Relative Strength Index (RSI) 62.51 35.99
Support Level $9.57 $16.49
Resistance Level $9.98 $21.61
Average True Range (ATR) 0.84 0.76
MACD 0.06 -0.16
Stochastic Oscillator 78.20 3.15

Price Performance

Historical Comparison
SHLS
DBVT

About SHLS Shoals Technologies Group Inc.

Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: